These data, together with results from other recent studies, indicate that metal complexes in general are well tolerated by the G. mellonella model. Compounds submitted to CO-ADD are generally not optimized for biological applications, hence any hits obtained through this screening will most likely have to undergo optimization for medicinal chemistry applications before a potential drug candidate is obtained. Regardless, we were interested to see if the excellent in vitro antifungal activity observed for metal complexes would translate to in vivo efficacy prior to any structural optimization for solubility, stability and other properties. To this end, we evaluated the ability of eight metal complexes to prolong survival in G. mellonella larvae infected with C. albicans. Compounds Pt1 and Pt2 showed some efficacy, and a subsequent log CFU reduction study revealed that treatment with Pt1, but not Pt2, resulted in a significant 0.7 log10 reduction in the treated larvae compared to the DMSO control. As mentioned earlier we have previously reported on Pt1 and related compounds for their activity against Gram-positive bacteria. Interestingly, in an analogous in vivo assay with G. mellonella infected with MRSA compound Pt1 did not elicit a significant reduction in bacterial load. It is notable that this compound class seems to perform well in assays against microbes while showing no toxicity against human cell lines or in G. mellonella.